Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect

We identified a germline missense mutation at nucleotide 505 (T to C) of the VHL tumor suppressor gene in 14, apparently unrelated, VHL type 2A families from the Black Forest region of Germany. This mutation was previously identified in two VHL 2A families living in Pennsylvania (USA). All affected individuals in the 16 families shared the same VHL haplotype indicating a founder effect. This missense mutation at codon 169 (Tyr to His) would probably cause an alteration in the structure of the putative VHL protein. The association of this distinct mutation with the pheochromocytoma phenotype in VHL may help to elucidate the genetic mechanism of carcinogenesis in this multi tumor cancer syndrome.

[1]  E. Sorscher,et al.  Diagnosis of genetic disease by primer-specified restriction map modification, with application to cystic fibrosis and retinitis pigmentosa , 1991, The Lancet.

[2]  K. Melmon,et al.  Lindau's disease: Review of the literature and study of a large kindred , 1964 .

[3]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[4]  P. Choyke,et al.  Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus , 1991, Human Genetics.

[5]  M. Lerman,et al.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.

[6]  Y. Nakamura,et al.  Specific genetic change in tumors associated with von Hippel-Lindau disease. , 1989, Journal of the National Cancer Institute.

[7]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[8]  D. Solomon,et al.  Renal pathology in von Hippel-Lindau disease. , 1988, Human pathology.

[9]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Shuin,et al.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. , 1994, Cancer research.

[11]  L. Schmidt,et al.  Three polymorphic dinucleotide repeats near the von Hippel Lindau (VHL) disease gene on human chromosome 3: D3S587; D3S1317; D3S1435. , 1993, Human Molecular Genetics.

[12]  W. Linehan,et al.  Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.

[13]  H. Neumann,et al.  Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. , 1993, The New England journal of medicine.

[14]  H. Neumann.  Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. , 1987, VASA. Zeitschrift fur Gefasskrankheiten.

[15]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[16]  B. Ponder,et al.  Erratum: Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours (Human Molecular Genetics (1994) 3 (237-241)) , 1994 .

[17]  Hsia Ye,et al.  von Hippel-Lindau disease affecting 43 members of a single kindred. , 1989 .

[18]  O. Wiestler,et al.  Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus , 1991, The Lancet.

[19]  Y. Hsia,et al.  Von Hippel‐Lindau Disease Affecting 43 Members of a Single Kindred , 1989, Medicine.

[20]  D. Clayton,et al.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC , 1994, Nature Genetics.

[21]  K. Yamakawa,et al.  Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p. , 1992, Human molecular genetics.

[22]  E. Petty,et al.  Mapping the gene for hereditary hyperparathyroidism and prolactinoma (MEN1Burin) to chromosome 11q: evidence for a founder effect in patients from Newfoundland. , 1994, American journal of human genetics.

[23]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.